Compare Novartis AG (NVS) vs PubMatic Inc (PUBM) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

PubMatic (PUBM) trades at $16.29, down 1.27% on the day, with a bullish technical signal driven by moving averages and recent support above the 20-day average. The company reported Q2 2026 revenue growth of 11% year-over-year and an EPS beat, though net income margins remain negative. Positive sentiment is fueled by AI-driven ad tech adoption and strategic hires, such as the new Global Chief Revenue Officer.

Outlook: Strong analyst consensus (64.7% buy ratings) and a $20.83 price target suggest upside potential from AI product momentum and cost controls. Risks include persistent profitability challenges and CFO transition uncertainty. The stock offers growth exposure but requires monitoring of margin improvement.